Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Testicular Torsion Evaluation by ultraSonography Technic Imaging

NCT07133243 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de Roubaix
Phase
Observational
Started
2025-11-03
Last updated
2025-08-20

Condition(s) studied

Testicular Torsion

Investigational drug(s) / intervention(s)

testicular ultrasound

testicular ultrasound: each patient will receive an testicular ultrasound to confirm diagnostic of testicular torsion

Study summary

The goal of this observational study is to assess the diagnostic concordance between testicular Doppler ultrasound of the spermatic cord vessels performed by an emergency physician and the diagnosis of testicular torsion made by the urologist during an exploration in the operating room (Gold standard) in men patients between 16 to 70 years old with suspicion of testicular torsion.

Participants will receive ultrasound performed by emergency physician during their visit to the emergency department. Results of this exam will be compare to gold standard. If the results are consistent, the investigators will have demonstrated the value of integrating ultrasound by the emergency physician into the management of testicular torsion.

Eligibility

Sex
MALE
Min age
16 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Male patients * Minimum age of 16 years and maximum age of 70 years * Presenting with unilateral testicular pain lasting less than 72 hours * Admitted to the Roubaix Hospital Emergency * Presence of an emergency physician trained in performing testicular ultrasound during the transition to the Emergency unit * Patient who did not object to participating in the study Exclusion Criteria: * Recent history (less than one month) of ipsilateral testicular torsion, testicular trauma, or testicular surgery * Patient with a history of sex reassignment, currently undergoing sex reassignment, or taking sex reassignment hormones * Innate or acquired absence of one of the two testicles within the scrotum * Patient who has already been included once in the TESTI study

Primary outcome measure(s)

  • Number of patient with diagnostic of testicular torsion — At enrollement
    Concordance between testicular ultrasound and chirurgical diagnostic of testicular torsion

Trial sites (1)

FacilityCityRegionStatus
CH de Roubaix Roubaix France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07133243 on ClinicalTrials.gov ↗ ← All trials in France